Skip to main content
Equibles
AMPH logo

AMPH · Amphastar Pharmaceuticals, Inc. · Metrics

Track AMPH — free

Use AMPH with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research AMPH.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$28.84 +0.35 (+1.23%) Play latest call Q3 2026 earnings call transcript
S&P 600 member Russell 2000 member Rebalance outlook locked
Market Cap
$1.22B
Shares
42.65M
Volume · Nov 9 34.62K Avg daily vol (3M) 479.76K

AMPH metrics

113 of 125 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$28.49
Market cap
$1.22B

Price action

23 metrics
Price change (1W)
+2.8%
Price change (30D)
+7.0%
Price change (3M)
+37.1%
Price change (6M)
+49.9%
Price change (YTD)
+6.4%
Price change (1Y)
+17.6%
Trailing year
Price change (5Y)
+41.9%
52-week high
$29.40
52-week low
$16.87
Change from 52-week high
-3.1%
Change from 52-week low
+68.9%
Annualized volatility
51.6%
Annualized volatility (3M)
32.7%
Implied volatility (30D)
49.5%
IV rank (1Y)
—
IV percentile (1Y)
—
Beta
0.5
RSI (14D)
66.7
Price vs SMA 50
+12.4%
Price vs SMA 200
+27.8%
Avg volume (3M)
479,758
Relative volume
1.7
Average dollar volume
$11.72M

Company

3 metrics
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Shares outstanding
42.65M

Valuation

12 metrics
P / E (TTM)
13.0
Trailing earnings · reciprocal yield 7.7%
PEG ratio
0.1
EV / revenue
2.1×
reciprocal yield 46.7%
EV / EBITDA
5.9×
reciprocal yield 16.9%
EV / EBIT
11.4×
reciprocal yield 8.7%
P / sales
1.6×
reciprocal yield 61.4%
P / book
1.5
reciprocal yield 67.0%
FCF yield
11.4%
TTM · current market cap
Buyback yield
7.9%
P / FCF
8.7
reciprocal yield 11.4%
P / operating cash flow
6.9
reciprocal yield 14.4%
Earnings yield
8.1%

Historical valuation

8 metrics
P / E historical average (3Y)
12.9×
reciprocal yield 7.7%
P / E historical average (5Y)
16.9×
reciprocal yield 5.9%
EV / revenue historical average (3Y)
2.7×
reciprocal yield 37.5%
EV / revenue historical average (5Y)
3.0×
reciprocal yield 33.7%
EV / EBIT historical average (3Y)
10.6×
reciprocal yield 9.4%
EV / EBIT historical average (5Y)
13.5×
reciprocal yield 7.4%
EV / EBITDA historical average (3Y)
13.9×
reciprocal yield 7.2%
EV / EBITDA historical average (5Y)
23.4×
reciprocal yield 4.3%

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
7.9%
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-11-05

Profitability

9 metrics
Gross margin
46.8%
Operating margin
18.7%
Trailing 12 months
Net margin
13.3%
Gross profit (TTM)
$349.09M
Operating profit (TTM)
$139.74M
Net income (TTM)
$98.96M
Trailing 12 months
Diluted EPS (TTM)
$2.19
FCF margin
18.6%
Effective tax rate
23.6%

Per share

11 metrics
Revenue per diluted share (TTM)
$16.51
Gross profit per diluted share (TTM)
$7.74
Operating profit per diluted share (TTM)
$3.12
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
$2.21
Operating cash flow per diluted share (TTM)
$3.88
Free cash flow per diluted share (TTM)
$3.08
Capital expenditures per diluted share (TTM)
$0.80
R&D per diluted share (TTM)
$2.03
Stock compensation per diluted share (TTM)
$0.65
Book value per share
$17.28

Growth

11 metrics
Revenue growth YoY
+8.2%
Year over year
Net income growth YoY
+117.7%
Revenue (TTM)
$745.79M
Trailing 12 months
EPS growth YoY
+135.1%
Shares change YoY
-9.0%
Year over year · fewer shares
Revenue CAGR (3Y)
+13.0%
Revenue CAGR (5Y)
+15.5%
EPS CAGR (3Y)
+5.3%
EPS CAGR (5Y)
+132.3%
FCF CAGR (3Y)
+23.0%
FCF CAGR (5Y)
+38.9%

Quality

14 metrics
Return on equity
12.1%
Return on assets
5.8%
Debt / equity
0.8
Current ratio
3.3
EBITDA (TTM)
$263.44M
Free cash flow (TTM)
$139.01M
Quick ratio
2.4
Interest coverage
5.3
Net debt / EBITDA
1.3
Return on invested capital
8.9%
Trailing 12 months
Net cash
−$382.37M
Latest balance sheet
Cash & equivalents
$204.59M
Total assets
$1.71B
Total debt
$613.00M

Cash flow & spend

7 metrics
Operating cash flow (TTM)
$175.33M
Capital expenditures (TTM)
$36.31M
R&D (TTM)
$92.29M
SG&A (TTM)
—
Stock compensation (TTM)
$29.58M
R&D / revenue
12.4%
Stock compensation / revenue
4.0%

Ownership (13F)

9 metrics
13F filers
212
13F filer change QoQ
-3
Institutional ownership
66.5%
Conviction holders (share of 13F filers)
0.0%
Crowding (high-turnover and private-fund holders)
21.0%
Private-fund adviser ownership
17.2%
Active holders' share change QoQ
-19.2%
Holder tenure
15.3
Price vs estimated holder cost
-28.2%

Ownership (registered funds)

1 metrics
Index-fund ownership
22.8%

Short interest

3 metrics
Short interest
10.2%
Latest settlement · 9.9 days to cover
Days to cover
9.9d
Short-squeeze score
85 / 100

Insider activity

2 metrics
Net insider buying (90D)
−$1.39M
Insider-sentiment score
28 / 100

Risk flags

1 metrics
Going concern
—
Key facts CIK 1297184 CUSIP 03209R103 13F (30d) 101 filings 88 filers Visit website Investor relations